Trending Company with an Optimistic Approach: Tiziana Life Sciences PLC [TLSA]

Considering what has happened in the past, let’s examine various historical developments regarding Tiziana Life Sciences PLC (NASDAQ: TLSA). For the last month, shares rose 71.30% and increased 2.96% over the past five days. Stock in the company fell -5.68% in the previous quarter. The company’s performance was positive at 89.11% since the calendar year started.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

Company Info

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored

Biotechnology company Tiziana Life Sciences Plc is a dual-listed company on the NASDAQ (NASDAQ: TLSA) and London Stock Exchange (LSE) that focuses on developing novel molecules to treat cancer, inflammation, and infectious diseases in humans.

Read More

Latest News

Tiziana Life Sciences has reported positive results from its explorational clinical study in Brazil investigating the treatment of COVID-19 patients by nasally administering Foralumab, its proprietary human monoclonal antibody against CD3 cells. In collaboration with Harvard Medical School (Boston, USA), and INTRIALS, a Latin American CRO based in So Paulo, Brazil, the clinical study was completed.

Recent studies suggest that COVID-19 is caused by an overreaction or abnormal host response by the immune system. Weight issues are also a risk factor for COVID-19, and obesity is linked to lower circulating T-cell suppression levels. Because of higher inflammation and insulin resistance, the lungs and other organs are damaged by high levels of inflammatory cytokines, chemokines, and free radicals. Therefore, nasal treatment with Foralumab, a fully human anti-CD3 mAb, modulating the immune system and stimulating Tregs is a scientifically logical approach to COVID-19 treatment. It is also one of the only monoclonal antibodies capable of causing systemic immunity via the nasal, respiratory tract, and gut epithelial lining. These studies proved the unique delivery system of Foralumab and its safety and efficacy as a potent anti-inflammatory therapeutic.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

Summary

In our lifetime, scientists are providing new insights into ways to prevent and treat diseases previously unknown. The pharmaceutical industry should offer investors huge returns if they can get their products approved by authorities.

Most Popular

Related posts